BC Innovations | Mar 7, 2018
Distillery Therapeutics


INDICATION: Breast cancer; colorectal cancer Cell culture studies suggest combining nitric oxide precursors with either TNFα or chemotherapies could help treat breast and colorectal cancers. In human and mouse breast and colorectal cancer cell lines,...
BC Week In Review | Feb 16, 2015
Clinical News

Generx cardionovo alferminogene tadenovec: Interim Phase III data

Interim data from 11 patients with myocardial ischemia due to coronary artery disease (CAD) in the open-label, Russian Phase III ASPIRE trial showed that an intracoronary infusion of Generx led to a 24.4% improvement in...
BC Week In Review | Apr 15, 2013
Company News

NovaDel, Suda deal

NovaDel will sell its NovaMist sublingual delivery technology along with other assets to Suda for an upfront payment of $400,000 plus 50 million shares of Suda stock and an option to purchase 10 million shares...
BC Week In Review | Apr 8, 2013
Company News

Apricus Biosciences, Biocodex, Mist Pharmaceuticals sales and marketing update

Apricus sold commercialization rights to two programs and said it is focusing resources on commercializing Vitaros alprostadil and developing Femprox alprostadil topical cream. Apricus sold North and South American commercialization rights for Totect dexrazoxane to...
BC Week In Review | Mar 18, 2013
Clinical News

Ranexa ranolazine: Phase IV data

The double-blind, international Phase IV TERISA trial in 927 evaluable chronic stable angina patients with concurrent Type II diabetes showed that Ranexa as an add-on to background antianginal therapy for 8 weeks met the primary...
BioCentury | Mar 18, 2013

Japan's biggest biotech

Japanese pharmaceutical companies have historically been thought of as stodgy, insular and opaque, but that is changing fast. One year into the job, Kyowa Hakko Kirin Co. Ltd. 's CEO is building his company along...
BC Week In Review | Jan 7, 2013
Company News

NovaDel, Suda deal

On Dec. 26, 2012, NovaDel said it granted Suda an option to acquire NovaMist sublingual delivery technology and other products. The companies declined to disclose financial terms. The option covers IP related to NovaMist, plus...
BC Week In Review | Nov 12, 2012
Clinical News

Cleviprex clevidipine: Phase III data

Top-line data from the open-label, international Phase III PRONTO trial in 104 emergency department hypertensive AHF patients who exhibited pulmonary congestion showed that IV clevidipine met the composite primary endpoint of median time and percent...
BioCentury | Jul 2, 2012

3Q Financial Markets Preview: Miles of milestones

A deep line-up of milestones could help retain gains the sector has been holding onto since 1Q12. In particular, investors would love to see further breakthroughs in difficult areas such as Alzheimer's disease and obesity....
BC Week In Review | Mar 26, 2012
Clinical News

Generx cardionovo alferminogene tadenovec: Phase III started

Cardium began the open-label, Russian Phase III ASPIRE trial to evaluate Generx administered through a standard cardiac infusion catheter in about 100 patients with myocardial ischemia due to coronary artery disease. Cardium Therapeutics Inc. (NYSE-A:CXM),...
Items per page:
1 - 10 of 235